Kadmon Corporation
Kadmon Corporation is a biopharmaceutical company that focuses on the discovery, development, and commercialization of innovative medicines. The company was founded in 2010 by Sam Waksal, who previously founded ImClone Systems, a biopharmaceutical company that was sold to Eli Lilly and Company in 2008.
History[edit | edit source]
Kadmon Corporation was established in 2010 by Sam Waksal. The company's initial focus was on the development of small molecules and biologics in the areas of oncology, immunology, and infectious disease. In 2016, Kadmon Corporation went public, trading on the New York Stock Exchange under the ticker symbol "KDMN".
Research and Development[edit | edit source]
Kadmon Corporation's research and development efforts are primarily focused on the areas of oncology, immunology, and infectious disease. The company's lead product candidate, KD025, is a ROCK2 inhibitor that is currently in Phase 2 clinical trials for the treatment of chronic graft-versus-host disease (cGVHD) and systemic sclerosis. Other product candidates in Kadmon's pipeline include KD033, an anti-PD-L1/IL-15 fusion protein, and KD045, a ROCK inhibitor for the treatment of fibrotic diseases.
Financials[edit | edit source]
As a publicly traded company, Kadmon Corporation's financial performance is reported on a quarterly and annual basis. The company's revenue primarily comes from product sales, licensing agreements, and research collaborations.
Criticism and Controversy[edit | edit source]
Kadmon Corporation has faced criticism and controversy, particularly in relation to its founder, Sam Waksal. Waksal has a history of legal troubles, including a conviction for insider trading while at ImClone Systems. Despite these controversies, Kadmon Corporation continues to operate and pursue its research and development goals.
See Also[edit | edit source]
- Biopharmaceutical
- Sam Waksal
- ImClone Systems
- Eli Lilly and Company
- New York Stock Exchange
- ROCK2 inhibitor
- Chronic graft-versus-host disease
- Systemic sclerosis
- Fibrotic diseases
References[edit | edit source]
Search WikiMD
Ad.Tired of being Overweight? Try W8MD's physician weight loss program.
Semaglutide (Ozempic / Wegovy and Tirzepatide (Mounjaro / Zepbound) available.
Advertise on WikiMD
|
WikiMD's Wellness Encyclopedia |
| Let Food Be Thy Medicine Medicine Thy Food - Hippocrates |
Translate this page: - East Asian
中文,
日本,
한국어,
South Asian
हिन्दी,
தமிழ்,
తెలుగు,
Urdu,
ಕನ್ನಡ,
Southeast Asian
Indonesian,
Vietnamese,
Thai,
မြန်မာဘာသာ,
বাংলা
European
español,
Deutsch,
français,
Greek,
português do Brasil,
polski,
română,
русский,
Nederlands,
norsk,
svenska,
suomi,
Italian
Middle Eastern & African
عربى,
Turkish,
Persian,
Hebrew,
Afrikaans,
isiZulu,
Kiswahili,
Other
Bulgarian,
Hungarian,
Czech,
Swedish,
മലയാളം,
मराठी,
ਪੰਜਾਬੀ,
ગુજરાતી,
Portuguese,
Ukrainian
Medical Disclaimer: WikiMD is not a substitute for professional medical advice. The information on WikiMD is provided as an information resource only, may be incorrect, outdated or misleading, and is not to be used or relied on for any diagnostic or treatment purposes. Please consult your health care provider before making any healthcare decisions or for guidance about a specific medical condition. WikiMD expressly disclaims responsibility, and shall have no liability, for any damages, loss, injury, or liability whatsoever suffered as a result of your reliance on the information contained in this site. By visiting this site you agree to the foregoing terms and conditions, which may from time to time be changed or supplemented by WikiMD. If you do not agree to the foregoing terms and conditions, you should not enter or use this site. See full disclaimer.
Credits:Most images are courtesy of Wikimedia commons, and templates, categories Wikipedia, licensed under CC BY SA or similar.
Contributors: Prab R. Tumpati, MD
